Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05365750 · ClinicalTrials.gov registry record
COVID-19 Antibody and Reinfection Study
A clinical trial, sponsored by Kaiser Permanente.
- Completed
- Registry status
- 4,235
- Enrollment target
NCT05365750: Completed study, sponsored by Kaiser Permanente.
NCT05365750 is a clinical trial that has completed, run by Kaiser Permanente. The registered enrollment target is 4,235 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05365750 has completed, sponsored by Kaiser Permanente.
- COMPLETED
- Registry status
- 4,235 participants
- Enrollment target
Study Summary
The goal of this study is to establish a cohort of Kaiser Permanente Colorado (KPCO) members who have and have not had COVID-19 infection for serial antibody testing and PCR testing to: 1. Quantify antibody titers among participants over 9 months. 2. Determine the rates of asymptomatic, mild, and severe recurrent infection among participants with prior COVID-19. 3. Examine association between antibody titer levels and risk of recurrent infection using a case control analysis nested in the cohort.
Primary Outcome
In this case-control analysis, case patients were participants with the outcome of reinfection. The date of reinfection was the index date. Control patients were those with a primary infection but without the outcome reinfection by the index date. The case and control participants were compared with respect to a seronegative test result (exposure) after primary infection and closest in time to the index date. Because the cases and controls were selected on the basis of the outcome, the seronegat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,235 participants |
| Start Date | 2020-06-15 |
| Est. Completion | 2024-12-31 |
What the finished NCT05365750 record still lists
NCT05365750 is an observational study that tracks outcomes without assigning an intervention. Its 4,235 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT05365750 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05365750 about?
NCT05365750 is a clinical study titled "COVID-19 Antibody and Reinfection Study". The goal of this study is to establish a cohort of Kaiser Permanente Colorado (KPCO) members who have and have not had COVID-19 infection for serial antibody testing and PCR testing to: 1. Quantify antibody titers among participants over 9 months. 2. Determine the rates of asymptomatic, mild, and s...
What is the current status of trial NCT05365750?
This trial is currently completed. The enrollment target is 4,235 participants. The study started on 2020-06-15. Estimated completion is 2024-12-31.
Who is sponsoring clinical trial NCT05365750?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06492616 · 4,220 participants · Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- NCT02693535 · 4,200 participants · Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- NCT05969028 · 4,200 participants · NA
First Responder Airway & Compression Rate Trial
- NCT06935370 · 4,200 participants · Phase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI